Vaccine Development Opportunity: Recombinant MVA Viruses for HIV Prevention and Treatment

Recombinant MVA Viruses Expressing Clade A/G and Clade B Modified HIV Env, Gag and Pol Genes Useful for HIV Vaccine Development | Office of Technology Transfer, NIH

 Vaccine Development Opportunity:

Recombinant MVA Viruses for HIV Prevention and Treatment

Image of HIV-infected T cells. Credit: NIAID

NIAID scientists in the Laboratory of Viral Diseases have developed recombinant modified vaccinia Ankara (MVA) viruses, which can be used to create prophylactic and therapeutic HIV vaccines. These recombinant viruses express modified or mutated HIV Env, Gag, and Pol proteins and have been shown to produce HIV virus-like particles that are immunogenic in mice. Recombinant viral vectors induce the same types of immune responses as live vaccines but are associated with less risk. Read more about this exciting collaboration/licensing opportunity: https://www.ott.nih.gov/technology/e-089-2002